Myriad, Gene and UnitedHealthcare

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer cover the company's genetic test that helps to determine which mental health medications are likely to work with an individual patient.
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight
Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
Myriad Genetics comments on UnitedHealthcare’s updated policy
Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to
Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests,
Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes
Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.
Myriad Genetics reports Q3 adjusted EPS 6c, consensus 2c
Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...
Business Wire11h
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) ...
Zacks.com on MSN11h
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 200% and 1.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
HighlightsThird quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on ...
Myriad: Q3 Earnings Snapshot
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...
bovnews3d
The Myriad Genetics, Inc. Rollercoaster: What’s Behind the Latest MYGN Stock Fluctuation?
On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...
Yahoo Finance13h
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics
Myriad Genetics (MYGN) reported $213.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.2%. EPS of $0.06 for the same period compares to -$0.03 ...
ETF Daily News3d
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $28.91 Consensus PT from Analysts
Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has earned a consensus recommendation of “Hold” from the twelve analysts that are currently covering the stock, Marketbeat.com reports.
Zacks.com on MSN1d
BIIB vs. MYGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...